BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:AbbVie readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies AbbVie's drugs run\, from Clinica
 lTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05822752-990@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Budigalimab: Phase 2 readout est. (NCT05822752)
DESCRIPTION:Budigalimab\, phase 2.\nStudy: Study to Evaluate Adverse Events
 \, and Change in Disease Activity\, When Intravenously (IV) Infused With L
 ivmoniplimab in Combination With IV Infused Budigalimab in Adult Participa
 nts With Hepatocellular Carcinoma (HCC)\nEstimated primary completion: Nov
 ember 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/budigalim
 ab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 5822752
URL:https://assetmemo.bio/drug/budigalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06395948-1285@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Zumilokibart: Phase 2 readout est. (NCT06395948)
DESCRIPTION:Zumilokibart\, phase 2\, Atopic Dermatitis.\nStudy: A Study Eva
 luating APG777 in Atopic Dermatitis\nEstimated primary completion: Novembe
 r 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/zumilokibart#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0639
 5948
URL:https://assetmemo.bio/drug/zumilokibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05456685-11140@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Elahere (Mirvetuximab soravtansine): Phase 2 readout est. (NCT05456
 685)
DESCRIPTION:Elahere (Mirvetuximab soravtansine)\, phase 2\, Ovarian Cancer.
 \nStudy: Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line 
 Treatment of Folate Receptor Alpha (FRα) Expressing\, Platinum-sensitive 
 Epithelial Ovarian Cancer\nEstimated primary completion: November 2026. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/mirvetuximab-soravtansi
 ne#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 5456685
URL:https://assetmemo.bio/drug/mirvetuximab-soravtansine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04895436-2078@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Venetoclax: Phase 2 readout est. (NCT04895436)
DESCRIPTION:Venetoclax\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy: St
 udy to Assess Change in Disease Activity and Adverse Events of Oral Veneto
 clax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurri
 ng Chronic Lymphocytic Leukemia (CLL)\nEstimated primary completion: Novem
 ber 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/venetoclax#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0489
 5436
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06846320-11137@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:ABBV-932: Phase 2 readout est. (NCT06846320)
DESCRIPTION:ABBV-932\, phase 2.\nStudy: Study to Assess Adverse Events and 
 Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant T
 herapies in Adult Participants With Generalized Anxiety Disorder\nEstimate
 d primary completion: November 2026. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/abbv-932#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT06846320
URL:https://assetmemo.bio/drug/abbv-932#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06389136-12@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Rinvoq (upadacitinib): Phase 3 readout est. (NCT06389136)
DESCRIPTION:Rinvoq (upadacitinib)\, phase 3\, Atopic Dermatitis.\nStudy: A 
 Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic
  Dermatitis and Inadequate Response to Dupilumab\nEstimated primary comple
 tion: November 2026. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 upadacitinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT06389136
URL:https://assetmemo.bio/drug/upadacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03989414-3132@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Elotuzumab: Phase 1/2 readout est. (NCT03989414)
DESCRIPTION:Elotuzumab\, phase 1/2\, Multiple Myeloma.\nStudy: A Study to D
 etermine the Recommended Dose and Regimen and to Evaluate the Safety and P
 reliminary Efficacy of CC-92480 in Combination With Standard Treatments in
  Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newl
 y Diagnosed Multiple Myeloma (NDMM)\nEstimated primary completion: 30 Nove
 mber 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/elotuzumab
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT039
 89414
URL:https://assetmemo.bio/drug/elotuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06107413-2270@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Telisotuzumab Adizutecan: Phase 2 readout est. (NCT06107413)
DESCRIPTION:Telisotuzumab Adizutecan\, phase 2\, Colorectal Cancer.\nStudy:
  Study to Assess Adverse Events and Change in Disease Activity in Previous
 ly Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unr
 esectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil
 \, Folinic Acid\, and Bevacizumab\nEstimated primary completion: December 
 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/telisotuzumab-a
 dizutecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT06107413
URL:https://assetmemo.bio/drug/telisotuzumab-adizutecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04704921-5173@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Surabgene lomparvovec: Phase 2/3 readout est. (NCT04704921)
DESCRIPTION:Surabgene lomparvovec\, phase 2/3\, Age-Related Macular Degener
 ation.\nStudy: Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gen
 e Therapy Administered Via Subretinal Delivery One Time in Participants Wi
 th nAMD\nEstimated primary completion: December 2026. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/surabgene-lomparvovec#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT04704921
URL:https://assetmemo.bio/drug/surabgene-lomparvovec#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06468228-103@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:lutikizumab: Phase 3 readout est. (NCT06468228)
DESCRIPTION:lutikizumab\, phase 3\, Hidradenitis Suppurativa.\nStudy: A Stu
 dy to Assess Disease Activity and Safety of Lutikizumab in Adult and Adole
 scent Participants With Moderate to Severe Hidradenitis Suppurativa\nEstim
 ated primary completion: December 2026. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/lutikizumab#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT06468228
URL:https://assetmemo.bio/drug/lutikizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03817502-803@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20261215
DTEND;VALUE=DATE:20261216
SUMMARY:Cariprazine (Vraylar): Phase 3 readout est. (NCT03817502)
DESCRIPTION:Cariprazine (Vraylar)\, phase 3\, Schizophrenia.\nStudy: Effica
 cy and Safety of Cariprazine in the Treatment of Adolescent Participants (
 13 to 17 Years of Age) With Schizophrenia\nEstimated primary completion: 1
 5 December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/cari
 prazine-vraylar#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT03817502
URL:https://assetmemo.bio/drug/cariprazine-vraylar#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01804686-2041@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Ibrutinib: Phase 3 readout est. (NCT01804686)
DESCRIPTION:Ibrutinib\, phase 3\, Diffuse Large B-Cell Lymphoma.\nStudy: A 
 Long-term Extension Study of PCI-32765 (Ibrutinib)\nEstimated primary comp
 letion: 31 December 2026. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/ibrutinib#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT01804686
URL:https://assetmemo.bio/drug/ibrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06109272-990@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Budigalimab: Phase 2/3 readout est. (NCT06109272)
DESCRIPTION:Budigalimab\, phase 2/3.\nStudy: A Study to Assess the Dose\, A
 dverse Events\, and Change in Disease Activity of Livmoniplimab as an Intr
 avenous (IV) Solution in Combination With Budigalimab as an IV Solution in
  Adult Participants With Hepatocellular Carcinoma (HCC)\nEstimated primary
  completion: January 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/budigalimab#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT06109272
URL:https://assetmemo.bio/drug/budigalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06701331-12@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Rinvoq (upadacitinib): Phase 3 readout est. (NCT06701331)
DESCRIPTION:Rinvoq (upadacitinib)\, phase 3\, Atopic Dermatitis.\nStudy: Sa
 fety and Efficacy of Upadacitinib in Combination With Topical Corticostero
 ids in Children From 2 to Less Than 12 Years of Age in Japan With Moderate
  to Severe Atopic Dermatitis\nEstimated primary completion: January 2027. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/upadacitinib#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT06701331
URL:https://assetmemo.bio/drug/upadacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04086264-2078@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Venetoclax: Phase 1/2 readout est. (NCT04086264)
DESCRIPTION:Venetoclax\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: IMGN63
 2 as Monotherapy or With Venetoclax and/or Azacitidine for Participants Wi
 th CD123-Positive Acute Myeloid Leukemia\nEstimated primary completion: Fe
 bruary 2027. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/venetocl
 ax#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 4086264
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06365853-11140@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Elahere (Mirvetuximab soravtansine): Phase 2 readout est. (NCT06365
 853)
DESCRIPTION:Elahere (Mirvetuximab soravtansine)\, phase 2\, Ovarian Cancer.
 \nStudy: A Study of Ocular Toxicity Evaluation and Mitigation During Treat
 ment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian
  Cancer With High Folate Receptor-Alpha Expression\nEstimated primary comp
 letion: February 2027. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/mirvetuximab-soravtansine#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT06365853
URL:https://assetmemo.bio/drug/mirvetuximab-soravtansine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06524635-103@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:lutikizumab: Phase 2 readout est. (NCT06524635)
DESCRIPTION:lutikizumab\, phase 2\, Atopic Dermatitis.\nStudy: A Study to A
 ssess Molecular Changes in Adult Participants With Moderate to Severe Hidr
 adenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receivin
 g Subcutaneous Injections of Lutikizumab\nEstimated primary completion: Fe
 bruary 2027. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/lutikizu
 mab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 06524635
URL:https://assetmemo.bio/drug/lutikizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06972446-103@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:lutikizumab: Phase 2 readout est. (NCT06972446)
DESCRIPTION:lutikizumab\, phase 2\, Rheumatoid Arthritis.\nStudy: A Study t
 o Evaluate Different Targeted Therapies for Patients With Rheumatoid Arthr
 itis\nEstimated primary completion: February 2027. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/lutikizumab#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT06972446
URL:https://assetmemo.bio/drug/lutikizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06632951-990@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Budigalimab: Phase 2 readout est. (NCT06632951)
DESCRIPTION:Budigalimab\, phase 2\, Urothelial Carcinoma.\nStudy: Study to 
 Evaluate Adverse Events and Change in Disease Activity When Intravenously 
 (IV) Infused Livmoniplimab is Used in Combination With IV Infused Budigali
 mab in Adult Participants With Urothelial Carcinoma (UC)\nEstimated primar
 y completion: March 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/budigalimab#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT06632951
URL:https://assetmemo.bio/drug/budigalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05451810-10986@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Epcoritamab: Phase 2 readout est. (NCT05451810)
DESCRIPTION:Epcoritamab\, phase 2\, Diffuse Large B-Cell Lymphoma.\nStudy: 
 A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Admini
 stered in the Outpatient Setting in Adult Participants With Relapsed or Re
 fractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma\nEs
 timated primary completion: March 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/epcoritamab#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT05451810
URL:https://assetmemo.bio/drug/epcoritamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07220460-11137@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:ABBV-932: Phase 2 readout est. (NCT07220460)
DESCRIPTION:ABBV-932\, phase 2.\nStudy: Study to Assess the Adverse Events 
 of Oral ABBV-932 in Adult Participants With Depressive Episodes Associated
  With Bipolar I or II Disorder\nEstimated primary completion: March 2027. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/abbv-932#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07220460
URL:https://assetmemo.bio/drug/abbv-932#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06063967-3@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Skyrizi (risankizumab): Phase 3 readout est. (NCT06063967)
DESCRIPTION:Skyrizi (risankizumab)\, phase 3\, Crohn's Disease.\nStudy: A S
 tudy to Assess Adverse Events and Change in Disease Activity of Risankizum
 ab Subcutaneous Induction Treatment for Moderately to Severely Active Croh
 n's Disease.\nEstimated primary completion: March 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/risankizumab#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT06063967
URL:https://assetmemo.bio/drug/risankizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05843643-12@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Rinvoq (upadacitinib): Phase 3 readout est. (NCT05843643)
DESCRIPTION:Rinvoq (upadacitinib)\, phase 3\, Systemic Lupus Erythematosus.
 \nStudy: Program to Assess Adverse Events and Change in Disease Activity o
 f Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic
  Lupus Erythematosus\nEstimated primary completion: March 2027. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/upadacitinib#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT05843643
URL:https://assetmemo.bio/drug/upadacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04777357-803@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Cariprazine (Vraylar): Phase 3 readout est. (NCT04777357)
DESCRIPTION:Cariprazine (Vraylar)\, phase 3\, Bipolar Disorder.\nStudy: A S
 tudy to Assess Change in Disease Activity and Adverse Events (AEs) With Ca
 riprazine in the Treatment of Depressive Episodes in Pediatric Participant
 s Participants (10 to 17 Years of Age) With Bipolar I Disorder.\nEstimated
  primary completion: March 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/cariprazine-vraylar#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT04777357
URL:https://assetmemo.bio/drug/cariprazine-vraylar#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05445778-11140@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Elahere (Mirvetuximab soravtansine): Phase 3 readout est. (NCT05445
 778)
DESCRIPTION:Elahere (Mirvetuximab soravtansine)\, phase 3\, Ovarian Cancer.
 \nStudy: Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as 
 Maintenance in Platinum-sensitive Epithelial Ovarian\, Fallopian Tube\, or
  Peritoneal Cancer\nEstimated primary completion: April 2027. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/mirvetuximab-soravtansine#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT05445778
URL:https://assetmemo.bio/drug/mirvetuximab-soravtansine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06718101-103@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:lutikizumab: Phase 2 readout est. (NCT06718101)
DESCRIPTION:lutikizumab\, phase 2\, Atopic Dermatitis.\nStudy: A Study to E
 valuate the Effectiveness and Safety of Treatments\, Either Alone or in Co
 mbination\, for the Treatment of Moderate to Severe Atopic Dermatitis\nEst
 imated primary completion: May 2027. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/lutikizumab#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT06718101
URL:https://assetmemo.bio/drug/lutikizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05125302-10391@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Ubrogepant (Ubrelvy): Phase 3 readout est. (NCT05125302)
DESCRIPTION:Ubrogepant (Ubrelvy)\, phase 3\, Migraine.\nStudy: Study to Ass
 ess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the
  Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)\nEsti
 mated primary completion: May 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/ubrogepant-ubrelvy#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT05125302
URL:https://assetmemo.bio/drug/ubrogepant-ubrelvy#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07462143-2698@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20270512
DTEND;VALUE=DATE:20270513
SUMMARY:RC148: Phase 2/3 readout est. (NCT07462143)
DESCRIPTION:RC148\, phase 2/3.\nStudy: A Phase Ⅱ/Ⅲ Clinical Trial of RC
 148 Plus Chemotherapy as 1L Therapy for Unresectable or Metastatic Colorec
 tal Cancer\nEstimated primary completion: 12 May 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/rc148#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT07462143
URL:https://assetmemo.bio/drug/rc148#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02899052-2078@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Venetoclax: Phase 2 readout est. (NCT02899052)
DESCRIPTION:Venetoclax\, phase 2\, Multiple Myeloma.\nStudy: Study of Venet
 oclax in Combination With Carfilzomib and Dexamethasone in Participants Wi
 th Relapsed or Refractory Multiple Myeloma (MM)\nEstimated primary complet
 ion: June 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/venet
 oclax#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT02899052
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05578976-10986@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Epcoritamab: Phase 3 readout est. (NCT05578976)
DESCRIPTION:Epcoritamab\, phase 3\, Diffuse Large B-Cell Lymphoma.\nStudy: 
 A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcori
 tamab Combined With Intravenous and Oral Rituximab\, Cyclophosphamide\, Do
 xorubicin Hydrochloride\, Vincristine\, and Prednisone (R-CHOP) or R-CHOP 
 in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (
 DLBCL)\nEstimated primary completion: June 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/epcoritamab#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT05578976
URL:https://assetmemo.bio/drug/epcoritamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03006068-12@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Rinvoq (upadacitinib): Phase 3 readout est. (NCT03006068)
DESCRIPTION:Rinvoq (upadacitinib)\, phase 3\, Ulcerative Colitis.\nStudy: A
  Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-
 494) in Participants With Ulcerative Colitis (UC)\nEstimated primary compl
 etion: July 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/upa
 dacitinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT03006068
URL:https://assetmemo.bio/drug/upadacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04401748-2078@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Venetoclax: Phase 3 readout est. (NCT04401748)
DESCRIPTION:Venetoclax\, phase 3.\nStudy: Study Of Venetoclax Tablet With I
 ntravenous or Subcutaneous Azacitidine to Assess Change in Disease Activit
 y In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic S
 yndrome\nEstimated primary completion: July 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/venetoclax#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT04401748
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06614192-2270@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Telisotuzumab Adizutecan: Phase 2 readout est. (NCT06614192)
DESCRIPTION:Telisotuzumab Adizutecan\, phase 2\, Colorectal Cancer.\nStudy:
  A Study Assessing Adverse Events and Disease Activity of Intravenously (I
 V) Infused Telisotuzumab Adizutecan in Adult Participants With c-Met Prote
 in Above Cutoff Level Above Refractory Metastatic Colorectal Cancer\nEstim
 ated primary completion: August 2027. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/telisotuzumab-adizutecan#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT06614192
URL:https://assetmemo.bio/drug/telisotuzumab-adizutecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06880744-3@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Skyrizi (risankizumab): Phase 3 readout est. (NCT06880744)
DESCRIPTION:Skyrizi (risankizumab)\, phase 3\, Ulcerative Colitis.\nStudy: 
 A Study to Assess the Change in Disease Activity in Adult Participants Wit
 h Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared
  to Vedolizumab\nEstimated primary completion: August 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/risankizumab#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT06880744
URL:https://assetmemo.bio/drug/risankizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03844048-2078@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Venetoclax: Phase 3 readout est. (NCT03844048)
DESCRIPTION:Venetoclax\, phase 3\, Acute Myeloid Leukemia.\nStudy: An Exten
 sion Study of Venetoclax for Subjects Who Have Completed a Prior Venetocla
 x Clinical Trial\nEstimated primary completion: August 2027. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/venetoclax#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT03844048
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04542824-10986@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Epcoritamab: Phase 1/2 readout est. (NCT04542824)
DESCRIPTION:Epcoritamab\, phase 1/2\, Diffuse Large B-Cell Lymphoma.\nStudy
 : Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects Wit
 h Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL)\nEs
 timated primary completion: September 2027. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/epcoritamab#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT04542824
URL:https://assetmemo.bio/drug/epcoritamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06257875-8@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Humira (adalimumab): Phase 2 readout est. (NCT06257875)
DESCRIPTION:Humira (adalimumab)\, phase 2\, Ulcerative Colitis.\nStudy: A S
 tudy to Assess Adverse Events and Change in Disease Activity From Intraven
 ous (IV) and Subcutaneous (SC) Lutikizumab in Adult Participants With Acti
 ve Ulcerative Colitis\nEstimated primary completion: September 2027. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/adalimumab#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT06257875
URL:https://assetmemo.bio/drug/adalimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07276997-837@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Icalcaprant: Phase 2 readout est. (NCT07276997)
DESCRIPTION:Icalcaprant\, phase 2\, Major Depressive Disorder.\nStudy: A St
 udy to Assess Change in Disease Activity and Adverse Events of Oral Icalca
 prant in Adult Participants With Major Depressive Disorder\nEstimated prim
 ary completion: September 2027. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/icalcaprant#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07276997
URL:https://assetmemo.bio/drug/icalcaprant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03345823-12@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Rinvoq (upadacitinib): Phase 3 readout est. (NCT03345823)
DESCRIPTION:Rinvoq (upadacitinib)\, phase 3\, Crohn's Disease.\nStudy: A Ma
 intenance and Long-Term Extension Study of the Efficacy and Safety of Upad
 acitinib (ABT-494) in Participants With Crohn's Disease Who Completed the 
 Studies M14-431 or M14-433\nEstimated primary completion: September 2027. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/upadacitinib#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT03345823
URL:https://assetmemo.bio/drug/upadacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04663347-10986@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Epcoritamab: Phase 1/2 readout est. (NCT04663347)
DESCRIPTION:Epcoritamab\, phase 1/2\, Diffuse Large B-Cell Lymphoma.\nStudy
 : Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B
 -cell Non-Hodgkin Lymphoma (B-NHL)\nEstimated primary completion: 30 Septe
 mber 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/epcoritama
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT04
 663347
URL:https://assetmemo.bio/drug/epcoritamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05201248-10986@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Epcoritamab: Phase 1/2 readout est. (NCT05201248)
DESCRIPTION:Epcoritamab\, phase 1/2.\nStudy: A Study to Evaluate Adverse Ev
 ents and Change in Disease Activity of Subcutaneous (SC) Epcoritamab As Mo
 notherapy or Combined With Standard of Care Therapies in Adult Participant
 s in China With B-Cell Non-Hodgkin Lymphoma\nEstimated primary completion:
  October 2027. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/epcori
 tamab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT05201248
URL:https://assetmemo.bio/drug/epcoritamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06772623-990@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Budigalimab: Phase 1/2 readout est. (NCT06772623)
DESCRIPTION:Budigalimab\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: S
 tudy to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuz
 umab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in 
 Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No 
 Prior Treatment for Advanced Disease\, and No Actionable Genomic Alteratio
 ns\nEstimated primary completion: November 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/budigalimab#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT06772623
URL:https://assetmemo.bio/drug/budigalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05757141-7528@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Fosigotifator: Phase 1/2 readout est. (NCT05757141)
DESCRIPTION:Fosigotifator\, phase 1/2.\nStudy: An Open-Label Exploratory St
 udy of Fosigotifator in Participants With Vanishing White Matter Disease\n
 Estimated primary completion: November 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/fosigotifator#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT05757141
URL:https://assetmemo.bio/drug/fosigotifator#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06696755-837@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Icalcaprant: Phase 2 readout est. (NCT06696755)
DESCRIPTION:Icalcaprant\, phase 2\, Bipolar Disorder.\nStudy: A Study to As
 sess Adverse Events and Change in Disease Activity of Oral Icalcaprant in 
 Adult Participants With Bipolar I or II Disorder\nEstimated primary comple
 tion: November 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 icalcaprant#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT06696755
URL:https://assetmemo.bio/drug/icalcaprant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06417775-10391@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Ubrogepant (Ubrelvy): Phase 3 readout est. (NCT06417775)
DESCRIPTION:Ubrogepant (Ubrelvy)\, phase 3\, Migraine.\nStudy: Study of Ora
 l Ubrogepant to Assess Adverse Events and Change in Disease Activity in Ad
 ult Participants With Menstrual Migraine\nEstimated primary completion: No
 vember 2027. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ubrogepa
 nt-ubrelvy#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT06417775
URL:https://assetmemo.bio/drug/ubrogepant-ubrelvy#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04623541-10986@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Epcoritamab: Phase 1/2 readout est. (NCT04623541)
DESCRIPTION:Epcoritamab\, phase 1/2.\nStudy: Safety and Efficacy Study of E
 pcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukem
 ia and Richter's Syndrome\nEstimated primary completion: December 2027. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/epcoritamab#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT04623541
URL:https://assetmemo.bio/drug/epcoritamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05139602-103@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:lutikizumab: Phase 2 readout est. (NCT05139602)
DESCRIPTION:lutikizumab\, phase 2\, Hidradenitis Suppurativa.\nStudy: A Stu
 dy to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-
 981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativ
 a Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy and Who Are Na
 ïve to Biologic Therapy\nEstimated primary completion: December 2027. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/lutikizumab#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT05139602
URL:https://assetmemo.bio/drug/lutikizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07874282-2698@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:RC148: Phase 2 readout est. (NCT07874282)
DESCRIPTION:RC148\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Phase II 
 Study to Evaluate Telisotuzumab Adizutecan in Combination With RC148(ABBV-
 1480) as First-Line Treatment for Patients With Non-Squamous Non-Small-Cel
 l Lung Cancer\nEstimated primary completion: December 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/rc148#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07874282
URL:https://assetmemo.bio/drug/rc148#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06158841-3132@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Elotuzumab: Phase 3 readout est. (NCT06158841)
DESCRIPTION:Elotuzumab\, phase 3\, Multiple Myeloma.\nStudy: Study Assessin
 g Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Avail
 able Therapies in Adult Participants With Relapsed or Refractory Multiple 
 Myeloma\nEstimated primary completion: December 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/elotuzumab#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT06158841
URL:https://assetmemo.bio/drug/elotuzumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05963074-2041@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20271215
DTEND;VALUE=DATE:20271216
SUMMARY:Ibrutinib: Phase 2 readout est. (NCT05963074)
DESCRIPTION:Ibrutinib\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy: A S
 tudy to Customize Ibrutinib Treatment Regimens for Participants With Previ
 ously Untreated Chronic Lymphocytic Leukemia\nEstimated primary completion
 : 15 December 2027. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/i
 brutinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT05963074
URL:https://assetmemo.bio/drug/ibrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07416474-2698@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:RC148: Phase 3 readout est. (NCT07416474)
DESCRIPTION:RC148\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: RC148 Plu
 s Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemothe
 rapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC)\nEstimat
 ed primary completion: 31 December 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/rc148#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07416474
URL:https://assetmemo.bio/drug/rc148#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07024784-11142@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:IMGN-151: Phase 2 readout est. (NCT07024784)
DESCRIPTION:IMGN-151\, phase 2.\nStudy: A Study to Assess Change in Disease
  Activity and Adverse Events in Adult Participants With Gynecologic Cancer
 s Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combinati
 on With Other Therapies\nEstimated primary completion: January 2028. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/imgn-151#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT07024784
URL:https://assetmemo.bio/drug/imgn-151#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05127954-10391@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Ubrogepant (Ubrelvy): Phase 3 readout est. (NCT05127954)
DESCRIPTION:Ubrogepant (Ubrelvy)\, phase 3\, Migraine.\nStudy: Long-term Ex
 tension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets
  for the Acute Treatment of Migraine in Pediatric Participants (Ages 6-17)
 \nEstimated primary completion: January 2028. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/ubrogepant-ubrelvy#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT05127954
URL:https://assetmemo.bio/drug/ubrogepant-ubrelvy#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06158854-3229@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Etentamig: Phase 1/2 readout est. (NCT06158854)
DESCRIPTION:Etentamig\, phase 1/2\, AL Amyloidosis.\nStudy: A Study to Asse
 ss Change in Disease Activity and Adverse Events (AE)s in Adult Participan
 ts With Immunoglobulin Light Chain (AL) Amyloidosis Receiving Etentamig (A
 BBV-383) as an Intravenous (IV) Infusion\nEstimated primary completion: Fe
 bruary 2028. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/etentami
 g#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06
 158854
URL:https://assetmemo.bio/drug/etentamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07145918-705@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Emraclidine: Phase 2 readout est. (NCT07145918)
DESCRIPTION:Emraclidine\, phase 2\, Schizophrenia.\nStudy: A Study to Asses
 s Adverse Events\, Change in Disease Activity\, and How Oral Emraclidine M
 oves Through the Body in Adult Participants With Schizophrenia\nEstimated 
 primary completion: February 2028. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/emraclidine#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07145918
URL:https://assetmemo.bio/drug/emraclidine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06568939-2230@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Telisotuzumab Vedotin: Phase 2 readout est. (NCT06568939)
DESCRIPTION:Telisotuzumab Vedotin\, phase 2\, Non-Small Cell Lung Cancer.\n
 Study: A Study to Assess Adverse Events and How Intravenously (IV) Infused
  Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy 
 in Adult Participants With Previously Treated Non-Squamous Non-Small Cell 
 Lung Cancer (NSCLC)\nEstimated primary completion: February 2028. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/telisotuzumab-vedotin#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT06568939
URL:https://assetmemo.bio/drug/telisotuzumab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04524611-3@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Skyrizi (risankizumab): Phase 3 readout est. (NCT04524611)
DESCRIPTION:Skyrizi (risankizumab)\, phase 3\, Crohn's Disease.\nStudy: Stu
 dy Comparing Intravenous (IV)/Subcutaneous (SC) Risankizumab to IV/SC Uste
 kinumab to Assess Change in Crohn's Disease Activity Index (CDAI) in Adult
  Participants With Moderate to Severe Crohn's Disease (CD)\nEstimated prim
 ary completion: February 2028. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/risankizumab#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT04524611
URL:https://assetmemo.bio/drug/risankizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07752979-172@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:ABBV-295: Phase 2 readout est. (NCT07752979)
DESCRIPTION:ABBV-295\, phase 2\, Obesity.\nStudy: Safety and Efficacy of AB
 BV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidit
 ies\nEstimated primary completion: March 2028. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/abbv-295#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07752979
URL:https://assetmemo.bio/drug/abbv-295#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06820463-2270@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Telisotuzumab Adizutecan: Phase 2 readout est. (NCT06820463)
DESCRIPTION:Telisotuzumab Adizutecan\, phase 2\, Colorectal Cancer.\nStudy:
  A Study to Evaluate the Adverse Events\, and Efficacy of Intravenous (IV)
  of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin\, Fluorour
 acil\, Folinic Acid/Leucovorin\, Bevacizumab\, Panitumumab in Adult Partic
 ipants With Metastatic Colorectal Cancer\nEstimated primary completion: Ma
 rch 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/telisotuzum
 ab-adizutecan#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT06820463
URL:https://assetmemo.bio/drug/telisotuzumab-adizutecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06118411-12@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Rinvoq (upadacitinib): Phase 3 readout est. (NCT06118411)
DESCRIPTION:Rinvoq (upadacitinib)\, phase 3\, Vitiligo.\nStudy: A Study To 
 Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Ad
 ult and Adolescent Participants With Vitiligo\nEstimated primary completio
 n: March 2028. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/upadac
 itinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT06118411
URL:https://assetmemo.bio/drug/upadacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06508658-10986@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Epcoritamab: Phase 3 readout est. (NCT06508658)
DESCRIPTION:Epcoritamab\, phase 3\, Diffuse Large B-Cell Lymphoma.\nStudy: 
 A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tabl
 ets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemci
 tabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or R
 efractory Diffuse Large B-Cell Lymphoma\nEstimated primary completion: Mar
 ch 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/epcoritamab#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0650
 8658
URL:https://assetmemo.bio/drug/epcoritamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06428019-2078@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Venetoclax: Phase 3 readout est. (NCT06428019)
DESCRIPTION:Venetoclax\, phase 3\, Chronic Lymphocytic Leukemia.\nStudy: A 
 Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Particip
 ants Receiving Oral Venetoclax in Combination With Intravenously Infused O
 binutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphoc
 ytic Leukemia (CLL)\nEstimated primary completion: March 2028. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/venetoclax#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT06428019
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05711394-10367@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Atogepant (Qulipta): Phase 3 readout est. (NCT05711394)
DESCRIPTION:Atogepant (Qulipta)\, phase 3\, Migraine.\nStudy: A Study to As
 sess the Adverse Events and Change in Disease Activity of Oral Atogepant T
 ablets in Pediatric Participants (6-17 Years of Age) With Episodic Migrain
 e\nEstimated primary completion: March 2028. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/atogepant-qulipta#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT05711394
URL:https://assetmemo.bio/drug/atogepant-qulipta#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04862286-3@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Skyrizi (risankizumab): Phase 3 readout est. (NCT04862286)
DESCRIPTION:Skyrizi (risankizumab)\, phase 3\, Psoriasis.\nStudy: Study to 
 Evaluate Adverse Events and Change in Disease Activity in Participants Bet
 ween 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With 
 Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participati
 on in Study M19-977\nEstimated primary completion: April 2028. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/risankizumab#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT04862286
URL:https://assetmemo.bio/drug/risankizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07592273-5173@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Surabgene lomparvovec: Phase 2/3 readout est. (NCT07592273)
DESCRIPTION:Surabgene lomparvovec\, phase 2/3.\nStudy: Surabgene Lomparvove
 c Administered in the Suprachoroidal Space in Adult Participants With Diab
 etic Retinopathy Without Center-Involved Diabetic Macular Edema\nEstimated
  primary completion: June 2028. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/surabgene-lomparvovec#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07592273
URL:https://assetmemo.bio/drug/surabgene-lomparvovec#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07387471-2078@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Venetoclax: Phase 2 readout est. (NCT07387471)
DESCRIPTION:Venetoclax\, phase 2.\nStudy: Study to Assess Change in Disease
  Activity of Oral Venetoclax in Adult Participants With Recurring Relapsed
  or Refractory (R/R) Waldenström Macroglobulinemia (WM)/Lymphoplasmacytic
  Lymphoma (LPL)\nEstimated primary completion: July 2028. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/venetoclax#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07387471
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07895355-2698@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:RC148: Phase 2 readout est. (NCT07895355)
DESCRIPTION:RC148\, phase 2.\nStudy: Phase II Clinical Study of RC148 (ABBV
 -1480) in Combination With Telisotuzumab Adizutecan (With or Without Chemo
 therapy) for Unresectable Colorectal Cancer\nEstimated primary completion:
  July 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/rc148#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0789535
 5
URL:https://assetmemo.bio/drug/rc148#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03768063-2078@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20280705
DTEND;VALUE=DATE:20280706
SUMMARY:Venetoclax: Phase 3 readout est. (NCT03768063)
DESCRIPTION:Venetoclax\, phase 3.\nStudy: A Study in Patients Previously En
 rolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizum
 ab Study\nEstimated primary completion: 5 July 2028. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/venetoclax#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT03768063
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04161898-12@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Rinvoq (upadacitinib): Phase 3 readout est. (NCT04161898)
DESCRIPTION:Rinvoq (upadacitinib)\, phase 3.\nStudy: A Study to Evaluate th
 e Efficacy and Safety of Upadacitinib in Participants With Takayasu Arteri
 tis (TAK)\nEstimated primary completion: August 2028. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/upadacitinib#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT04161898
URL:https://assetmemo.bio/drug/upadacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05782907-12@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Rinvoq (upadacitinib): Phase 3 readout est. (NCT05782907)
DESCRIPTION:Rinvoq (upadacitinib)\, phase 3\, Ulcerative Colitis.\nStudy: S
 tudy to Assess Adverse Events\, Change in Disease Activity\, and How Oral 
 Upadacitinib Moves Through the Body of Pediatric Participants With Moderat
 ely to Severely Active Ulcerative Colitis.\nEstimated primary completion: 
 August 2028. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/upadacit
 inib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T05782907
URL:https://assetmemo.bio/drug/upadacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05889182-12@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Rinvoq (upadacitinib): Phase 3 readout est. (NCT05889182)
DESCRIPTION:Rinvoq (upadacitinib)\, phase 3\, Hidradenitis Suppurativa.\nSt
 udy: A Study to Assess Change in Disease Activity and Adverse Events of Or
 al Upadacitinib in Adult and Adolescent Participants With Moderate to Seve
 re Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy\nEstimated pr
 imary completion: August 2028. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/upadacitinib#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT05889182
URL:https://assetmemo.bio/drug/upadacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07769502-2270@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Telisotuzumab Adizutecan: Phase 2 readout est. (NCT07769502)
DESCRIPTION:Telisotuzumab Adizutecan\, phase 2.\nStudy: A Study to Assess A
 dverse Events and Change in Disease Activity With Treatment Combinations W
 ith Telisotuzumab Adizutecan in Adults Participants With Pancreatobiliary 
 Cancers\nEstimated primary completion: September 2028. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/telisotuzumab-adizutecan#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07769502
URL:https://assetmemo.bio/drug/telisotuzumab-adizutecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03398135-3@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Skyrizi (risankizumab): Phase 3 readout est. (NCT03398135)
DESCRIPTION:Skyrizi (risankizumab)\, phase 3\, Ulcerative Colitis.\nStudy: 
 A Study to Assess the Efficacy and Safety of Risankizumab in Participants 
 With Ulcerative Colitis\nEstimated primary completion: September 2028. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/risankizumab#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT03398135
URL:https://assetmemo.bio/drug/risankizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03999801-5173@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Surabgene lomparvovec: Phase 2 readout est. (NCT03999801)
DESCRIPTION:Surabgene lomparvovec\, phase 2\, Age-Related Macular Degenerat
 ion.\nStudy: Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy\
 nEstimated primary completion: December 2028. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/surabgene-lomparvovec#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT03999801
URL:https://assetmemo.bio/drug/surabgene-lomparvovec#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07933536-172@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:ABBV-295: Phase 2 readout est. (NCT07933536)
DESCRIPTION:ABBV-295\, phase 2.\nStudy: A Study to Assess Targeted Therapie
 s for Treatment of Adults With Moderate to Severe Psoriasis\nEstimated pri
 mary completion: December 2028. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/abbv-295#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07933536
URL:https://assetmemo.bio/drug/abbv-295#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04928846-2230@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Telisotuzumab Vedotin: Phase 3 readout est. (NCT04928846)
DESCRIPTION:Telisotuzumab Vedotin\, phase 3\, Non-Small Cell Lung Cancer.\n
 Study: A Study to Assess Disease Activity and Adverse Events of Intravenou
 s (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participant
 s With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)\
 nEstimated primary completion: December 2028. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/telisotuzumab-vedotin#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT04928846
URL:https://assetmemo.bio/drug/telisotuzumab-vedotin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03625037-10986@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20290131
DTEND;VALUE=DATE:20290201
SUMMARY:Epcoritamab: Phase 1/2 readout est. (NCT03625037)
DESCRIPTION:Epcoritamab\, phase 1/2\, Large B-Cell Lymphoma.\nStudy: First-
 in-Human (FIH) Trial in Patients With Relapsed\, Progressive or Refractory
  B-Cell Lymphoma\nEstimated primary completion: January 2029. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/epcoritamab#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT03625037
URL:https://assetmemo.bio/drug/epcoritamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07059845-11140@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20290131
DTEND;VALUE=DATE:20290201
SUMMARY:Elahere (Mirvetuximab soravtansine): Phase 2 readout est. (NCT07059
 845)
DESCRIPTION:Elahere (Mirvetuximab soravtansine)\, phase 2\, Ovarian Cancer.
 \nStudy: A Study to Assess Adverse Events and Change in Disease Activity o
 f Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansi
 ne in Adult Participants With Ovarian Cancer\nEstimated primary completion
 : January 2029. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/mirve
 tuximab-soravtansine#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT07059845
URL:https://assetmemo.bio/drug/mirvetuximab-soravtansine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03105102-3@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20290228
DTEND;VALUE=DATE:20290301
SUMMARY:Skyrizi (risankizumab): Phase 3 readout est. (NCT03105102)
DESCRIPTION:Skyrizi (risankizumab)\, phase 3\, Crohn's Disease.\nStudy: A S
 tudy of the Efficacy and Safety of Risankizumab in Participants With Crohn
 's Disease\nEstimated primary completion: February 2029. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/risankizumab#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT03105102
URL:https://assetmemo.bio/drug/risankizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07023302-12@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20290228
DTEND;VALUE=DATE:20290301
SUMMARY:Rinvoq (upadacitinib): Phase 3 readout est. (NCT07023302)
DESCRIPTION:Rinvoq (upadacitinib)\, phase 3\, Alopecia Areata.\nStudy: A St
 udy to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Ad
 ult and Adolescent Participants in Japan With Alopecia Areata\nEstimated p
 rimary completion: February 2029. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/upadacitinib#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07023302
URL:https://assetmemo.bio/drug/upadacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07423104-2078@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20290201
DTEND;VALUE=DATE:20290202
SUMMARY:Venetoclax: Phase 2 readout est. (NCT07423104)
DESCRIPTION:Venetoclax\, phase 2\, Acute Myeloid Leukemia.\nStudy: A Study 
 of Cladribine\, Low Dose Cytarabine\, and Venetoclax in Treatment of Relap
 sed/Refractory or Secondary Acute Myeloid Leukemia\nEstimated primary comp
 letion: 1 February 2029. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/venetoclax#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07423104
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04499248-11139@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:AGN-193408: Phase 1/2 readout est. (NCT04499248)
DESCRIPTION:AGN-193408\, phase 1/2\, Open-Angle Glaucoma.\nStudy: AGN-19340
 8 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension\nEstim
 ated primary completion: April 2029. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/agn-193408#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT04499248
URL:https://assetmemo.bio/drug/agn-193408#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07155174-11131@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:ABBV-706: Phase 2 readout est. (NCT07155174)
DESCRIPTION:ABBV-706\, phase 2\, Small Cell Lung Cancer.\nStudy: A Study to
  Evaluate the Optimal Dose\, Adverse Events and Change in Disease Activity
  of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard 
 of Care as First-Line Treatment in Adult Participants With Previously Untr
 eated Extensive Stage Small Cell Lung Cancer\nEstimated primary completion
 : April 2029. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/abbv-70
 6#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 155174
URL:https://assetmemo.bio/drug/abbv-706#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05995353-3@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:Skyrizi (risankizumab): Phase 3 readout est. (NCT05995353)
DESCRIPTION:Skyrizi (risankizumab)\, phase 3\, Crohn's Disease.\nStudy: A S
 tudy to Assess Adverse Events\, Change in Disease Activity\, and How Intra
 venous and Subcutaneous Risankizumab Moves Through the Body of Pediatric P
 articipants With Moderately to Severely Active Crohn's Disease\nEstimated 
 primary completion: April 2029. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/risankizumab#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT05995353
URL:https://assetmemo.bio/drug/risankizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07525206-2270@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20290531
DTEND;VALUE=DATE:20290601
SUMMARY:Telisotuzumab Adizutecan: Phase 3 readout est. (NCT07525206)
DESCRIPTION:Telisotuzumab Adizutecan\, phase 3\, Colorectal Cancer.\nStudy:
  A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combinatio
 n With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combin
 ation With Oral Trifluridine and Tipiracil in Adult Participants With Refr
 actory Metastatic Colorectal Cancer\nEstimated primary completion: May 202
 9. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/telisotuzumab-adiz
 utecan#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07525206
URL:https://assetmemo.bio/drug/telisotuzumab-adizutecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05609630-12@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Rinvoq (upadacitinib): Phase 3 readout est. (NCT05609630)
DESCRIPTION:Rinvoq (upadacitinib)\, phase 3.\nStudy: Study of Oral Upadacit
 inib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Diseas
 e Activity\, Adverse Events and How Drug Moves Through the Body of Pediatr
 ic and Adolescent Participants With Active Systemic Juvenile Idiopathic Ar
 thritis.\nEstimated primary completion: June 2029. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/upadacitinib#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT05609630
URL:https://assetmemo.bio/drug/upadacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07904754-11133@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20290731
DTEND;VALUE=DATE:20290801
SUMMARY:ABBV-722: Phase 2 readout est. (NCT07904754)
DESCRIPTION:ABBV-722\, phase 2.\nStudy: Platform Study of Targeted Therapie
 s for Adults With Moderately to Severely Active Rheumatoid Arthritis\nEsti
 mated primary completion: July 2029. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/abbv-722#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT07904754
URL:https://assetmemo.bio/drug/abbv-722#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06865105-3@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20290831
DTEND;VALUE=DATE:20290901
SUMMARY:Skyrizi (risankizumab): Phase 2 readout est. (NCT06865105)
DESCRIPTION:Skyrizi (risankizumab)\, phase 2\, Psoriatic Arthritis.\nStudy:
  Study of Targeted Therapies for the Treatment of Adult Participants With 
 Active Psoriatic Arthritis\nEstimated primary completion: August 2029. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/risankizumab#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT06865105
URL:https://assetmemo.bio/drug/risankizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07160179-5184@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20291031
DTEND;VALUE=DATE:20291101
SUMMARY:ABBV-6628: Phase 1/2 readout est. (NCT07160179)
DESCRIPTION:ABBV-6628\, phase 1/2\, Age-Related Macular Degeneration.\nStud
 y: Study to Assess the Adverse Events and How Intravitreal ABBV-6628 Moves
  Through the Body of Adult Participants With Geographic Atrophy Secondary 
 to Age-Related Macular Degeneration\nEstimated primary completion: October
  2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/abbv-6628#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07160179
URL:https://assetmemo.bio/drug/abbv-6628#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07744126-2270@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20291031
DTEND;VALUE=DATE:20291101
SUMMARY:Telisotuzumab Adizutecan: Phase 2 readout est. (NCT07744126)
DESCRIPTION:Telisotuzumab Adizutecan\, phase 2.\nStudy: A Study to Assess A
 dverse Events\, Change in Disease Activity and Optimal Dose of Intravenous
  (IV) Telisotuzumab Adizutecan With IV Pembrolizumab for First-Line Treatm
 ent of Adult Participants With Recurrent or Metastatic Head and Neck Squam
 ous Cell Carcinoma\nEstimated primary completion: October 2029. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/telisotuzumab-adizutecan#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07744126
URL:https://assetmemo.bio/drug/telisotuzumab-adizutecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07023289-2270@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20291130
DTEND;VALUE=DATE:20291201
SUMMARY:Telisotuzumab Adizutecan: Phase 2 readout est. (NCT07023289)
DESCRIPTION:Telisotuzumab Adizutecan\, phase 2\, Colorectal Cancer.\nStudy:
  A Study to Assess Adverse Events and Change in Disease Activity in Adult 
 Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alon
 e or With Standard of Care in Participants With Post Adjuvant Circulating 
 Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disea
 se\nEstimated primary completion: November 2029. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/telisotuzumab-adizutecan#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07023289
URL:https://assetmemo.bio/drug/telisotuzumab-adizutecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06461897-12@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20291130
DTEND;VALUE=DATE:20291201
SUMMARY:Rinvoq (upadacitinib): Phase 3 readout est. (NCT06461897)
DESCRIPTION:Rinvoq (upadacitinib)\, phase 3\, Atopic Dermatitis.\nStudy: A 
 Study to Assess Adverse Events and Change in Disease Activity Comparing Or
 al Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 
 12 Years of Age With Moderate to Severe Atopic Dermatitis\nEstimated prima
 ry completion: November 2029. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/upadacitinib#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT06461897
URL:https://assetmemo.bio/drug/upadacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07003425-1285@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Zumilokibart: Phase 2 readout est. (NCT07003425)
DESCRIPTION:Zumilokibart\, phase 2\, Atopic Dermatitis.\nStudy: A Long-term
  Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis\nEstimat
 ed primary completion: December 2029. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/zumilokibart#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07003425
URL:https://assetmemo.bio/drug/zumilokibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05409066-10986@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Epcoritamab: Phase 3 readout est. (NCT05409066)
DESCRIPTION:Epcoritamab\, phase 3\, Follicular Lymphoma.\nStudy: Study of S
 ubcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral
  Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity
  in Adult Participants With Follicular Lymphoma\nEstimated primary complet
 ion: December 2029. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/e
 pcoritamab#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT05409066
URL:https://assetmemo.bio/drug/epcoritamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07756645-2698@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:RC148: Phase 3 readout est. (NCT07756645)
DESCRIPTION:RC148\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: A Study t
 o Assess Intravenous ABBV-1480 Combined With Chemotherapy Versus Pembroliz
 umab Combined With Chemotherapy for the First Line Treatment of Locally Ad
 vanced/Metastatic Non-Small Cell Lung Cancer in Adult Participants\nEstima
 ted primary completion: December 2029. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/rc148#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07756645
URL:https://assetmemo.bio/drug/rc148#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06548542-3@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20300131
DTEND;VALUE=DATE:20300201
SUMMARY:Skyrizi (risankizumab): Phase 2 readout est. (NCT06548542)
DESCRIPTION:Skyrizi (risankizumab)\, phase 2\, Crohn's Disease.\nStudy: Stu
 dy of Targeted Therapies for the Treatment of Adult Participants With Mode
 rate to Severe Crohn's Disease\nEstimated primary completion: January 2030
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/risankizumab#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT06548542
URL:https://assetmemo.bio/drug/risankizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06890338-11140@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20300228
DTEND;VALUE=DATE:20300301
SUMMARY:Elahere (Mirvetuximab soravtansine): Phase 2 readout est. (NCT06890
 338)
DESCRIPTION:Elahere (Mirvetuximab soravtansine)\, phase 2\, Ovarian Cancer.
 \nStudy: A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infus
 ed Carboplatin With Mirvetuximab Soravtansine in Participants With Newly D
 iagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epit
 helial Ovarian\, Fallopian Tube or Primary Peritoneal Cancer.\nEstimated p
 rimary completion: February 2030. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/mirvetuximab-soravtansine#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT06890338
URL:https://assetmemo.bio/drug/mirvetuximab-soravtansine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07821684-2270@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20300331
DTEND;VALUE=DATE:20300401
SUMMARY:Telisotuzumab Adizutecan: Phase 3 readout est. (NCT07821684)
DESCRIPTION:Telisotuzumab Adizutecan\, phase 3\, Non-Small Cell Lung Cancer
 .\nStudy: A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan Comp
 ared to Standard of Care in Adult Participants Previously Treated\, EGFR W
 ildtype\, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Can
 cer\nEstimated primary completion: March 2030. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/telisotuzumab-adizutecan#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07821684
URL:https://assetmemo.bio/drug/telisotuzumab-adizutecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06012240-12@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20300430
DTEND;VALUE=DATE:20300501
SUMMARY:Rinvoq (upadacitinib): Phase 3 readout est. (NCT06012240)
DESCRIPTION:Rinvoq (upadacitinib)\, phase 3\, Alopecia Areata.\nStudy: A St
 udy to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Ad
 ult and Adolescent Participants With Severe Alopecia Areata\nEstimated pri
 mary completion: April 2030. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/upadacitinib#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT06012240
URL:https://assetmemo.bio/drug/upadacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07935369-2698@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20300430
DTEND;VALUE=DATE:20300501
SUMMARY:RC148: Phase 2/3 readout est. (NCT07935369)
DESCRIPTION:RC148\, phase 2/3.\nStudy: RC118 Combined With RC148 as First-L
 ine Treatment for Claudin 18.2-Positive\, HER2-Negative Advanced G/GEJ Ade
 nocarcinoma\nEstimated primary completion: 30 April 2030. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/rc148#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT07935369
URL:https://assetmemo.bio/drug/rc148#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07155187-2270@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20300930
DTEND;VALUE=DATE:20301001
SUMMARY:Telisotuzumab Adizutecan: Phase 2/3 readout est. (NCT07155187)
DESCRIPTION:Telisotuzumab Adizutecan\, phase 2/3\, Non-Small Cell Lung Canc
 er.\nStudy: A Study to Assess Adverse Events and Change in Disease Activit
 y of Intravenous (IV) Telisotuzumab Adizutecan\, Monotherapy or in Combina
 tion With Osimertinib\, Compared to Standard of Care in Adult Participants
  With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small C
 ell Lung Cancer\nEstimated primary completion: September 2030. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/telisotuzumab-adizutecan#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07155187
URL:https://assetmemo.bio/drug/telisotuzumab-adizutecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07365241-11131@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20300930
DTEND;VALUE=DATE:20301001
SUMMARY:ABBV-706: Phase 3 readout est. (NCT07365241)
DESCRIPTION:ABBV-706\, phase 3\, Small Cell Lung Cancer.\nStudy: A Study to
  Evaluate Adverse Events and Change in Disease Activity of Intravenous ABB
 V-706 Versus Standard of Care in Adult Participants With Relapsed/Refracto
 ry Small Cell Lung Cancer\nEstimated primary completion: September 2030. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/abbv-706#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT07365241
URL:https://assetmemo.bio/drug/abbv-706#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07599670-671@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20301031
DTEND;VALUE=DATE:20301101
SUMMARY:ABBV-1758: Phase 1/2 readout est. (NCT07599670)
DESCRIPTION:ABBV-1758\, phase 1/2\, Alzheimer's Disease.\nStudy: A Study to
  Assess the Safety and Effects of ABBV-1758 Following Subcutaneous or Intr
 avenous Injections in Participants With Alzheimer's Disease\nEstimated pri
 mary completion: October 2030. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/abbv-1758#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07599670
URL:https://assetmemo.bio/drug/abbv-1758#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06628310-990@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20301031
DTEND;VALUE=DATE:20301101
SUMMARY:Budigalimab: Phase 2 readout est. (NCT06628310)
DESCRIPTION:Budigalimab\, phase 2.\nStudy: A Study to Evaluate the Adverse 
 Events\, Efficacy\, and Optimal Dose of Intravenous (IV) ABBV-400 in Combi
 nation With IV Fluorouracil\, Leucovorin\, and Budigalimab in Adult Partic
 ipants With Locally Advanced Unresectable or Metastatic Gastric\, Gastroes
 ophageal Junction\, or Esophageal Adenocarcinoma\nEstimated primary comple
 tion: October 2030. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/b
 udigalimab#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT06628310
URL:https://assetmemo.bio/drug/budigalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06953960-3229@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Etentamig: Phase 1/2 readout est. (NCT06953960)
DESCRIPTION:Etentamig\, phase 1/2\, Multiple Myeloma.\nStudy: A Study to As
 sess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alo
 ne or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in A
 dult Participants With Multiple Myeloma (MM)\nEstimated primary completion
 : December 2030. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/eten
 tamig#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT06953960
URL:https://assetmemo.bio/drug/etentamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02966756-2078@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Venetoclax: Phase 2 readout est. (NCT02966756)
DESCRIPTION:Venetoclax\, phase 2\, Chronic Lymphocytic Leukemia.\nStudy: A 
 Study of Venetoclax in Participants With Relapsed or Refractory Chronic Ly
 mphocytic Leukemia/Small Lymphocytic Lymphoma\nEstimated primary completio
 n: December 2030. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ven
 etoclax#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT02966756
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07196644-2270@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Telisotuzumab Adizutecan: Phase 2 readout est. (NCT07196644)
DESCRIPTION:Telisotuzumab Adizutecan\, phase 2.\nStudy: A Study to Assess A
 dverse Events and Change in Disease Activity in Participants 12 Years of A
 ge or Older With Locally Advanced or Metastatic Solid Tumors That Harbor M
 ET Amplification Receiving Intravenously Infused Telisotuzumab Adizutecan\
 nEstimated primary completion: December 2030. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/telisotuzumab-adizutecan#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07196644
URL:https://assetmemo.bio/drug/telisotuzumab-adizutecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06332534-12@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20310131
DTEND;VALUE=DATE:20310201
SUMMARY:Rinvoq (upadacitinib): Phase 3 readout est. (NCT06332534)
DESCRIPTION:Rinvoq (upadacitinib)\, phase 3\, Crohn's Disease.\nStudy: Croh
 n's Disease: Efficacy\, Safety\, and Pharmacokinetics of Upadacitinib in P
 ediatric Subjects With Moderately to Severely Active Crohn's Disease\nEsti
 mated primary completion: January 2031. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/upadacitinib#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT06332534
URL:https://assetmemo.bio/drug/upadacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06810505-10367@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20310331
DTEND;VALUE=DATE:20310401
SUMMARY:Atogepant (Qulipta): Phase 3 readout est. (NCT06810505)
DESCRIPTION:Atogepant (Qulipta)\, phase 3\, Migraine.\nStudy: A Study of Or
 al Atogepant Tablets to Assess Adverse Events and Change in Disease Activi
 ty To Prevent Migraine in Participants Aged 12 to 17 Years\nEstimated prim
 ary completion: March 2031. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/atogepant-qulipta#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT06810505
URL:https://assetmemo.bio/drug/atogepant-qulipta#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07829549-2698@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20310430
DTEND;VALUE=DATE:20310501
SUMMARY:RC148: Phase 3 readout est. (NCT07829549)
DESCRIPTION:RC148\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: Phase III
  Study of RC148 Plus Chemotherapy Versus Tislelizumab Plus Chemotherapy as
  First-Line Treatment for Non-Squamous Non-Small Cell Lung Cancer Without 
 Actionable Genomic Alterations\nEstimated primary completion: April 2031. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/rc148#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07829549
URL:https://assetmemo.bio/drug/rc148#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03314181-2078@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20310531
DTEND;VALUE=DATE:20310601
SUMMARY:Venetoclax: Phase 2 readout est. (NCT03314181)
DESCRIPTION:Venetoclax\, phase 2\, Multiple Myeloma.\nStudy: A Study of Com
 bination Therapy With Venetoclax\, Daratumumab and Dexamethasone (With and
  Without Bortezomib) in Participants With Relapsed or Refractory Multiple 
 Myeloma\nEstimated primary completion: May 2031. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/venetoclax#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT03314181
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07490301-2270@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20310630
DTEND;VALUE=DATE:20310701
SUMMARY:Telisotuzumab Adizutecan: Phase 2/3 readout est. (NCT07490301)
DESCRIPTION:Telisotuzumab Adizutecan\, phase 2/3.\nStudy: A Study to Assess
  Intravenous (IV) Telisotuzumab Adizutecan in Combination With Fluorouraci
 l\, Folinic Acid\, and Oxaliplatin (FOLFOX) Compared to Standard of Care i
 n Adult Participants With First-Line Metastatic Pancreatic Ductal Adenocar
 cinoma\nEstimated primary completion: June 2031. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/telisotuzumab-adizutecan#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07490301
URL:https://assetmemo.bio/drug/telisotuzumab-adizutecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07895056-11131@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20310831
DTEND;VALUE=DATE:20310901
SUMMARY:ABBV-706: Phase 2 readout est. (NCT07895056)
DESCRIPTION:ABBV-706\, phase 2\, Small Cell Lung Cancer.\nStudy: A Study to
  Assess Adverse Events and Change in Disease Activity of Intravenous (IV) 
 ABBV-706 in Combination With Tarlatamab and Atezolizumab in Adult Particip
 ants With Extensive Stage-Small Cell Lung Cancer\nEstimated primary comple
 tion: August 2031. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ab
 bv-706#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07895056
URL:https://assetmemo.bio/drug/abbv-706#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07697456-3@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20311031
DTEND;VALUE=DATE:20311101
SUMMARY:Skyrizi (risankizumab): Phase 2 readout est. (NCT07697456)
DESCRIPTION:Skyrizi (risankizumab)\, phase 2\, Ulcerative Colitis.\nStudy: 
 Study of Advanced Therapies for the Treatment of Adult Participants With M
 oderately to Severely Active Crohn's Disease or Ulcerative Colitis\nEstima
 ted primary completion: October 2031. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/risankizumab#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07697456
URL:https://assetmemo.bio/drug/risankizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06236438-990@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20311031
DTEND;VALUE=DATE:20311101
SUMMARY:Budigalimab: Phase 2/3 readout est. (NCT06236438)
DESCRIPTION:Budigalimab\, phase 2/3\, Non-Small Cell Lung Cancer.\nStudy: S
 tudy to Evaluate Adverse Events\, Optimal Dose\, and Change in Disease Act
 ivity\, With Livmoniplimab in Combination With Budigalimab Plus Chemothera
 py Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants
  With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
 \nEstimated primary completion: October 2031. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/budigalimab#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT06236438
URL:https://assetmemo.bio/drug/budigalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07895043-11131@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20311231
DTEND;VALUE=DATE:20320101
SUMMARY:ABBV-706: Phase 2 readout est. (NCT07895043)
DESCRIPTION:ABBV-706\, phase 2\, Small Cell Lung Cancer.\nStudy: A Study to
  Assess Adverse Events and Change in Disease Activity of Intravenous (IV) 
 ABBV-706 in Combination With Alveltamig and Atezolizumab for Adults Partic
 ipants With Extensive Stage-Small Cell Lung Cancer\nEstimated primary comp
 letion: December 2031. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/abbv-706#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07895043
URL:https://assetmemo.bio/drug/abbv-706#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07772492-12@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20320331
DTEND;VALUE=DATE:20320401
SUMMARY:Rinvoq (upadacitinib): Phase 3 readout est. (NCT07772492)
DESCRIPTION:Rinvoq (upadacitinib)\, phase 3\, Alopecia Areata.\nStudy: A St
 udy to Evaluate the Safety and Effectiveness of Upadacitinib in Pediatric 
 Participants With Alopecia Areata\nEstimated primary completion: March 203
 2. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/upadacitinib#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT07772492
URL:https://assetmemo.bio/drug/upadacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05707949-10367@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20320430
DTEND;VALUE=DATE:20320501
SUMMARY:Atogepant (Qulipta): Phase 3 readout est. (NCT05707949)
DESCRIPTION:Atogepant (Qulipta)\, phase 3\, Migraine.\nStudy: Long-term Ext
 ension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatr
 ic Participants (6 to 17 Years of Age) With Migraine\nEstimated primary co
 mpletion: April 2032. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /atogepant-qulipta#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT05707949
URL:https://assetmemo.bio/drug/atogepant-qulipta#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07581002-2078@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20320630
DTEND;VALUE=DATE:20320701
SUMMARY:Venetoclax: Phase 2/3 readout est. (NCT07581002)
DESCRIPTION:Venetoclax\, phase 2/3\, Acute Myeloid Leukemia.\nStudy: A Stud
 y to Assess Adverse Events and Change in Disease Activity When Intravenous
  (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and 
 IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Le
 ukemia (AML)\nEstimated primary completion: June 2032. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/venetoclax#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07581002
URL:https://assetmemo.bio/drug/venetoclax#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07896434-12@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20320831
DTEND;VALUE=DATE:20320901
SUMMARY:Rinvoq (upadacitinib): Phase 3 readout est. (NCT07896434)
DESCRIPTION:Rinvoq (upadacitinib)\, phase 3\, Vitiligo.\nStudy: A Study to 
 Learn How Effective\, Safe\, and Tolerable Upadacitinib is for Young Parti
 cipants With Non-segmental Vitiligo\nEstimated primary completion: August 
 2032. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/upadacitinib#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT078964
 34
URL:https://assetmemo.bio/drug/upadacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05283720-10986@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20321130
DTEND;VALUE=DATE:20321201
SUMMARY:Epcoritamab: Phase 2 readout est. (NCT05283720)
DESCRIPTION:Epcoritamab\, phase 2.\nStudy: A Study to Evaluate Adverse Even
 ts and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Comb
 ination With Oral and Intravenous Anti-Neoplastic Agents in Adult Particip
 ants With Non-Hodgkin Lymphoma\nEstimated primary completion: November 203
 2. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/epcoritamab#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT05283720
URL:https://assetmemo.bio/drug/epcoritamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07728188-3229@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20330228
DTEND;VALUE=DATE:20330301
SUMMARY:Etentamig: Phase 3 readout est. (NCT07728188)
DESCRIPTION:Etentamig\, phase 3\, Multiple Myeloma.\nStudy: A Study to Eval
 uate Adverse Events and Change in Disease Activity With Injected Etentamig
  Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed 
 or Refractory Multiple Myeloma\nEstimated primary completion: February 203
 3. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/etentamig#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07728188
URL:https://assetmemo.bio/drug/etentamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07007065-5173@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20330331
DTEND;VALUE=DATE:20330401
SUMMARY:Surabgene lomparvovec: Phase 3 readout est. (NCT07007065)
DESCRIPTION:Surabgene lomparvovec\, phase 3\, Age-Related Macular Degenerat
 ion.\nStudy: Study to Assess the Injection Burden\, Adverse Events\, Chang
 e in Disease Activity\, and Long-Term Preservation of Visual Acuity of Sur
 abgene Lomparvovec in Adult Participants With Neovascular Age-Related Macu
 lar Degeneration (nAMD)\nEstimated primary completion: March 2033. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/surabgene-lomparvovec#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07007065
URL:https://assetmemo.bio/drug/surabgene-lomparvovec#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07071519-3@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20340731
DTEND;VALUE=DATE:20340801
SUMMARY:Skyrizi (risankizumab): Phase 3 readout est. (NCT07071519)
DESCRIPTION:Skyrizi (risankizumab)\, phase 3\, Ulcerative Colitis.\nStudy: 
 A Study to Learn More About How Risankizumab Works in Young Participants W
 ith Ulcerative Colitis\nEstimated primary completion: July 2034. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/risankizumab#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT07071519
URL:https://assetmemo.bio/drug/risankizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07793422-3229@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20341231
DTEND;VALUE=DATE:20350101
SUMMARY:Etentamig: Phase 3 readout est. (NCT07793422)
DESCRIPTION:Etentamig\, phase 3\, AL Amyloidosis.\nStudy: Study to Evaluate
  Change in Disease Activity and Adverse Events of Subcutaneous Etentamig C
 ompared With Daratumumab Plus Cyclophosphamide Plus Bortezomib Plus Dexame
 thasone (Dara-CyBorD) in Adults With Amyloid Light Chain (AL) Amyloidosis\
 nEstimated primary completion: December 2034. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/etentamig#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07793422
URL:https://assetmemo.bio/drug/etentamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07933211-12@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20350630
DTEND;VALUE=DATE:20350701
SUMMARY:Rinvoq (upadacitinib): Phase 2/3 readout est. (NCT07933211)
DESCRIPTION:Rinvoq (upadacitinib)\, phase 2/3.\nStudy: A Study to Evaluate 
 the Safety and Efficacy (How Well the Study Treatment Works) of ABBV-2294 
 in Adult Participants With Systemic Sclerosis That Are Currently Receiving
  Local Standard of Care Treatment\, and to Determine the Best Dose of ABBV
 -2294 to be Evaluated Further.\nEstimated primary completion: June 2035. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/upadacitinib#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT07933211
URL:https://assetmemo.bio/drug/upadacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06892522-3229@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20351231
DTEND;VALUE=DATE:20360101
SUMMARY:Etentamig: Phase 1/2 readout est. (NCT06892522)
DESCRIPTION:Etentamig\, phase 1/2\, Multiple Myeloma.\nStudy: A Study to As
 sess Change in Disease Activity and Adverse Events (AE)s in Adult Particip
 ants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antib
 odies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations\nEst
 imated primary completion: December 2035. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/etentamig#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT06892522
URL:https://assetmemo.bio/drug/etentamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07005102-2270@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20361130
DTEND;VALUE=DATE:20361201
SUMMARY:Telisotuzumab Adizutecan: Phase 2/3 readout est. (NCT07005102)
DESCRIPTION:Telisotuzumab Adizutecan\, phase 2/3\, Non-Small Cell Lung Canc
 er.\nStudy: A Study to Assess Adverse Events\, Change in Disease Activity 
 of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as
  First-Line Treatment in Adult Participants With Locally Advanced Unresect
 able or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer\nE
 stimated primary completion: November 2036. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/telisotuzumab-adizutecan#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07005102
URL:https://assetmemo.bio/drug/telisotuzumab-adizutecan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06191744-10986@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20371130
DTEND;VALUE=DATE:20371201
SUMMARY:Epcoritamab: Phase 3 readout est. (NCT06191744)
DESCRIPTION:Epcoritamab\, phase 3\, Follicular Lymphoma.\nStudy: Study of S
 ubcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral
  Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity
  in Adult Participants With Previously Untreated Follicular Lymphoma\nEsti
 mated primary completion: November 2037. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/epcoritamab#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT06191744
URL:https://assetmemo.bio/drug/epcoritamab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07095452-3229@assetmemo.bio
DTSTAMP:20261121T004059Z
DTSTART;VALUE=DATE:20410331
DTEND;VALUE=DATE:20410401
SUMMARY:Etentamig: Phase 2/3 readout est. (NCT07095452)
DESCRIPTION:Etentamig\, phase 2/3\, Multiple Myeloma.\nStudy: A Study to As
 sess A Change in Disease Activity and Adverse Events of Intravenous Etenta
 mig and Daratumumab (Etentamig+D) Compared to Daratumumab\, Lenalidomide\,
  and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multip
 le Myeloma Not Eligible for Transplant\nEstimated primary completion: Marc
 h 2041. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/etentamig#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0709545
 2
URL:https://assetmemo.bio/drug/etentamig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
